{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:15:51Z","timestamp":1793506551594,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.annonc.2024.06.015","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T20:28:02Z","timestamp":1719952082000},"page":"882-891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":132,"title":["Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial"],"prefix":"10.1016","volume":"35","author":[{"given":"Z.Y.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.M.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.F.","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.X.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-9553","authenticated-orcid":false,"given":"Y.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.N.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.J.","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.L.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.K.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.G.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.Z.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.X.","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2024.06.015_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.annonc.2024.06.015_bib2","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3390\/cancers13061374","article-title":"Emerging trends for radio-immunotherapy in rectal cancer","volume":"13","author":"Corr\u00f2","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.annonc.2024.06.015_bib3","article-title":"Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer","volume":"8","author":"Stary","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2024.06.015_bib4","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2020.38.15_suppl.4100","article-title":"Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"38","author":"Yuki","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.06.015_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2023.41.4_suppl.108","volume":"41","author":"Tsukada","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.06.015_bib6","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2021.39.15_suppl.3511","article-title":"Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): the AVANA study","volume":"39","author":"Salvatore","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.06.015_bib7","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/j.annonc.2021.05.054","article-title":"SO-30 efficacy and safety of neoadjuvant short-course radiation followed by mfolfox-6 plus avelumab for locally-advanced rectal adenocarcinoma: averectal study","volume":"32","author":"Shamseddine","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.06.015_bib8","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.annonc.2023.04.162","article-title":"P-106 The neoadjuvant rectal (NAR) score application in the context of total neoadjuvant treatment with chemo-immuno-radiation for locally advanced rectal cancer: data from the phase II Averectal study","volume":"34","author":"Chehade","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2024.06.015_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/bjs.5506","article-title":"Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer (Polish I)","volume":"93","author":"Bujko","year":"2006","journal-title":"Br J Surg"},{"issue":"31","key":"10.1016\/j.annonc.2024.06.015_bib10","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04","volume":"30","author":"Ngan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.06.015_bib11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1470-2045(17)30086-4","article-title":"Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial","volume":"18","author":"Erlandsson","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2024.06.015_bib12","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2024.06.015_bib13","unstructured":"National Comprehensive Cancer Network: NCCN Guidelines Version 6.2023 Rectal Cancer."},{"issue":"3","key":"10.1016\/j.annonc.2024.06.015_bib14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.annonc.2024.06.015_bib15","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ijrobp.2006.02.050","article-title":"Definition and delineation of the clinical target volume for rectal cancer","volume":"65","author":"Roels","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.annonc.2024.06.015_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.radonc.2007.12.005","article-title":"The quality assurance process for the ARTSCAN head and neck study - a practical interactive approach for QA in 3DCRT and IMRT","volume":"87","author":"Johansson","year":"2008","journal-title":"Radiother Oncol"},{"issue":"35","key":"10.1016\/j.annonc.2024.06.015_bib17","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1200\/JCO.2011.37.7176","article-title":"Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer","volume":"29","author":"Maas","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2024.06.015_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41571-021-00538-5","article-title":"International consensus recommendations on key outcome measures for organ preservation after (chemo) radiotherapy in patients with rectal cancer","volume":"18","author":"Fokas","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.06.015_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2024.06.015_bib20","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/annonc\/mdz186","article-title":"Long-course preoperative chemoradiation versus 5\u00a0\u00d7 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study","volume":"30","author":"Cise\u0142","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.06.015_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2003.12.006","article-title":"Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy (Polish I)","volume":"72","author":"Bujko","year":"2004","journal-title":"Radiother Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2024.06.015_bib22","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2024.06.015_bib23","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3390\/cells9092071","article-title":"Radiotherapy scheme effect on PD-L1 expression for locally advanced rectal cancer","volume":"9","author":"Boustani","year":"2020","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.annonc.2024.06.015_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.06.015_bib25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.annonc.2024.06.015_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijrobp.2018.01.071","article-title":"Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy","volume":"101","author":"Lan","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2024.06.015_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40425-016-0149-6","article-title":"A\u00a0hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"4","author":"Crocenzi","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2024.06.015_bib28","article-title":"Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: a new era for anal preservation","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.annonc.2024.06.015_bib29","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial (NRG-GI002)","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2024.06.015_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.annonc.2024.06.015_bib31","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S1470-2045(20)30024-3","article-title":"Outcome measures in multimodal rectal cancer trials","volume":"21","author":"Fokas","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.06.015_bib32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.21037\/jgo.2017.01.10","article-title":"Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis","volume":"8","author":"Petrelli","year":"2017","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.06.015_bib33","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2024.06.015_bib34","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery\u2013a five-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"issue":"44","key":"10.1016\/j.annonc.2024.06.015_bib35","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1038\/s41388-023-02835-y","article-title":"Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer","volume":"42","author":"Kasi","year":"2023","journal-title":"Oncogene"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424007464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424007464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T03:02:07Z","timestamp":1726110127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424007464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0923753424007464"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.06.015","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}